The challenge has been in early detection of inflammation. Matrix metalloproteinase-9 (MMP-9), an inflammatory biomarker consistently elevated in the tears of dry eye patients, may accelerate early diagnosis when detected.
AXIM Biotechnologies, Inc. recently announced that it has successfully developed a rapid quantitative tear test for MMP-9, an inflammatory biomarker for Dry Eye Disease.
The company is an international healthcare solutions company targeting dry eye disease (DED), an under-diagnosed, though common disease, in part because symptoms do not always correlate with objective signs. DED has a highly variable symptom profile at different stages of the disease, and there is often a discordance between signs and symptoms.
The challenge has been in early detection of inflammation. Matrix metalloproteinase-9 (MMP-9), an inflammatory biomarker consistently elevated in the tears of dry eye patients, may accelerate early diagnosis when detected.
